IP Library Granted Patent US 10,702,601
Granted Patent B2
US 10,702,601 · App. 15/920,565 · Granted Jul 7, 2020

Porcine epidemic diarrhea virus vaccine

Inventors: Luis Alejandro Hernandez (Story City, IA); Arun V. Iyer (Ames, IA); Dianna M. Murphy Jordan (Ames, IA); Abby Rae Patterson (Story City, IA); Michael B. Roof (Ames, IA); Eric Martin Vaughn (Ames, IA); Joseph Gilbert Victoria (Ames, IA)
A61K39/215A61K45/06C07K14/005C07K14/165C07K16/10C12N7/00A61K2039/5252A61K2039/552C07K2317/76C12N2710/14043C12N2710/14143C12N2770/20021C12N2770/20022C12N2770/20034C12N2770/20063
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,601
App. No.
15/920,565
Granted
Jul 7, 2020
Kind
B2
Abstract

The present invention relates to immunogenic compositions, wherein the immunogenic compositions include a recombinant spike antigen porcine epidemic diarrhea virus (PEDV). The immunogenic compositions commonly include an oil-in-water emulsion as an adjuvant. Methods for producing the immunogenic compositions and the recombinant PEDV spike antigen are also provided.

Claims (30)

1. An immunogenic composition comprising a recombinant spike antigen of porcine epidemic diarrhea virus (PEDV) having a heterologous C-terminal domain and a heterologous transmembrane domain, and an oil-in-water emulsion as an adjuvant, wherein the porcine epidemic diarrhea virus (PEDV) is a PEDV of North American origin and

a. wherein the spike antigen is encoded by a nucleic acid sequence that is at least 95% identical with SEQ ID NO: 8 over the length of SEQ ID NO: 8.

2. The immunogenic composition of claim 1 , wherein the recombinant antigen comprises one or more immunogenic components selected from the group consisting of:

a. an isolated nucleic acid encoding an antigen of porcine epidemic diarrhea virus (PEDV) spike protein, wherein the antigen has at least 95% homology with SEQ ID NO:3, 7, 9 or 14,

b. a recombinant vector comprising the isolated nucleic acid of a),

c. the recombinant PEDV Spike protein encoded by the nucleic acid of a), and

d. any combination thereof.

3. The immunogenic composition of claim 2 , wherein such immunogenic composition comprises a pharmaceutical acceptable carrier and/or an excipient.

4. The immunogenic composition of claim 1 , wherein the oil-in-water emulsion is an EMULSIGEN® oil-in-water emulsion-based adjuvant.

5. The immunogenic composition of claim 2 , wherein an immunogenic component is the isolated nucleic acid.

6. The immunogenic composition of claim 2 , wherein an immunogenic component is the recombinant vector.

7. The immunogenic composition of claim 2 , wherein an immunogenic component is the recombinant porcine epidemic diarrhea virus (PEDV) Spike protein.

8. The immunogenic composition of claim 2 , wherein an immunogenic component is a combination.

9. The immunogenic composition of claim 2 , further comprising at least one additional antigen associated with a pathogen other than porcine epidemic diarrhea virus.

10. A kit for inducing an immunogenic response in a pig against porcine epidemic diarrhea virus (PEDV) comprising:

a. a dispenser capable of administering an immunogenic composition to a pig; and

b. the immunogenic composition according to claim 2 .

11. A method of producing an immunogenic composition comprising:

a. expressing an antigen of porcine epidemic diarrhea virus (PEDV) comprising the recombinant antigen of claim 2 in a host cell,

b. harvesting the antigen of porcine epidemic diarrhea virus (PEDV) cells, and

c. adding an oil-in-water emulsion-based adjuvant to the porcine epidemic diarrhea virus (PEDV) antigen of step b).

12. The method of claim 11 , wherein the PEDV antigen comprises:

a. an isolated nucleic acid encoding an antigen of porcine epidemic diarrhea virus (PEDV) spike protein, wherein the recombinant Spike polypeptide has at least 95% homology with SEQ ID NO:3, 7, 9 or 14,

b. a recombinant vector comprising the isolated nucleic acid of a),

c. the recombinant PEDV Spike protein encoded by the nucleic acid of a), and

d. any combination thereof.

13. The method of claim 11 , wherein the antigen of porcine epidemic diarrhea virus (PEDV) is expressed by a recombinant baculovirus vector.

14. The method of claim 13 , wherein the antigen of porcine epidemic diarrhea virus (PEDV) is expressed in insect cells.

15. The method of claim 11 , wherein the oil-in-water emulsion-based adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.

16. A method for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV), comprising administering to such pig the vaccine of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2019
From: HERNANDEZ, LUIS ALEJANDRO; IYER, ARUN V.; JORDAN, DIANNA M. MURPHY; PATTERSON, ABBY RAE; ROOF, MICHAEL B.; VAUGHN, ERIC MARTIN; VICTORIA, JOSEPH GILBERT
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 050972/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2019
From: BOEHRINGER INGELHEIM VETMEDICA, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 050304/0549 →
Continuity (3)
Continuation 14672631 · Mar 30, 2015
Provisional Application 61974722 · Apr 3, 2014
Related Publication 20180207260A1 · Jul 26, 2018